Capital Performance Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Capital Performance Advisors’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$60.5K	Sell	25,975 -76	-0.3%	-$161	﹤0.01%	308
2026 Q1	$56.5K	Buy	26,051 +76	+0.3%	+$189	﹤0.01%	462
2025 Q4	$46.8K	Hold	25,975	–	–	﹤0.01%	443
2025 Q3	$57.7K	Sell	25,975 -1	-0%	-$2	0.01%	344
2025 Q2	$38.4K	Hold	25,976	–	–	0.01%	268
2025 Q1	$66.5K	Hold	25,976	–	–	0.01%	255
2024 Q4	$48.8K	Hold	25,976	–	–	0.02%	161
2024 Q3	$26.5K	Sell	25,976 -817	-3%	-$859	0.01%	520
2024 Q2	$31.3K	Buy	26,793 +535	+2%	+$632	0.01%	90
2024 Q1	$33.1K	Buy	26,258 +283	+1%	+$423	0.01%	83
2023 Q4	$46.2K	Buy	25,975 +1	+0%	+$2	0.02%	76
2023 Q3	$43.1K	Hold	25,974	–	–	0.02%	56
2023 Q2	$51.9K	Hold	25,974	–	–	0.03%	59
2023 Q1	$54.5K	Hold	25,974	–	–	0.03%	53
2022 Q4	$35.6K	Hold	25,974	–	–	0.02%	50
2022 Q3	$27K	Hold	25,974	–	–	0.02%	45
2022 Q2	$28K	Buy	+25,974	New	+$30.4K	0.02%	46

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Capital Performance Advisors's PLX Position: Q2 2026 in Review

Capital Performance Advisors reduced its Protalix BioTherapeutics (PLX) stake by 0.29% in Q2 2026, selling an estimated $161 and leaving 25,975 shares worth $60.5K. The position accounts for ﹤0.01% of the portfolio, ranked #308.

Capital Performance Advisors first reported a position in PLX in Q2 2022 and has held it in 17 quarters since. The position peaked at $66.5K in Q1 2025. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Capital Performance Advisors held 25,975 shares of Protalix BioTherapeutics worth $60.5K as of Q2 2026.
Capital Performance Advisors sold 76 Protalix BioTherapeutics shares in Q2 2026, an estimated $161.
Protalix BioTherapeutics made up ﹤0.01% of Capital Performance Advisors's portfolio in Q2 2026, its #308 holding.
Capital Performance Advisors first reported a position in Protalix BioTherapeutics in Q2 2022 and has held it in 17 quarters since.
Capital Performance Advisors's Protalix BioTherapeutics position peaked at $66.5K in Q1 2025.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Capital Performance Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.